Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
What to Expect During PT 141 Treatment Patients receive a clinical assessment before starting PT 141
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
With significant or rapid weight loss, particularly when driven by GLP-1 drugs, several mechanisms converge: Loss of underlying fat volume removes structural support Collagen and elastin fibres become stretched and fragmented Speed of weight loss outpaces skin contraction While some rebound occurs naturally, significant laxity can be permanent, especially after large weight reductions
This direct central nervous system activity helps explain the mood improvements many users experience
